Project description
Strategic pan-European approach to combat antimicrobial resistance
Antimicrobial resistance (AMR) causes numerous losses of lives worldwide. Antibiotic treatments need stratification to improve patient outcomes and limit the impact of AMR. The EU-funded VALUE-Dx project aims to develop policy and regulatory recommendations and understand value indicators and barriers for the adoption of community-acquired acute respiratory tract infections (CA-ARTI) diagnostics. The consortium of 6 in vitro diagnostic companies and 20 non-industry partners will define clinical algorithms and user requirements for CA-ARTI diagnostic tests. The value of diagnostics will be tested and demonstrated using pan-European clinical and laboratory research infrastructure, employing the innovative adaptive trial designs to evaluate novel CA-ARTI diagnostics.
Objective
Antimicrobial resistance (AMR) is of great public health concern, causing numerous losses of lives worldwide and threatening to reverse many of the considerable strides modern medicine has made over the last century. There is a need to stratify antibiotic and alternative treatments in terms of the actual benefit for the patient, improving patient outcome and limit the impact on AMR. High quality, effective and appropriate diagnostic tests to steer appropriate use of antibiotics are available. However, implementation of these tests into daily healthcare practice is hampered due to lack of insight in the medical, technological and health economical value and limited knowledge about psychosocial, ethical, regulatory and organisational barriers to their implementation into clinical practice.
VALUE-Dx will define and understand these value indicators and barriers to adoption of diagnostics of Community-Acquired Acute Respiratory Tract Infections (CA-ARTI) in order to develop and improve health economic models to generate insight in the whole value of diagnostics and develop policy and regulatory recommendations. In addition, efficient clinical algorithms and user requirement specifications of tests will be developed fuelling the medical and technological value of CA-ARTI diagnostics. The value of diagnostics will be tested and demonstrated in a unique pan-European clinical and laboratory research infrastructure allowing for innovative adaptive trial designs to evaluate novel CA-ARTI diagnostics. Close and continuous interaction with the VALUE-Dx multi-stakeholder platform provides for optimal alignment of VALUE-Dx activities with stakeholder opinions, expert knowledge and interests.
A variety of dissemination and advocacy measures will promote wide-spread adoption of clinical and cost-effective innovative diagnostics to achieve more personalized, evidence-based antibiotic prescription in order to transform clinical practice, improve patient outcomes and combat AMR.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
2000 Antwerpen
Belgium
See on map
Participants (26)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
2650 Edegem
See on map
OX1 2JD Oxford
See on map
3584 CX Utrecht
See on map
35127 Padova
See on map
37129 Verona
See on map
EH8 9YL Edinburgh
See on map
9713 GZ Groningen
See on map
31096 Haifa
See on map
26006 La Rioja
See on map
02215 Boston Ma
See on map
69007 Lyon
See on map
1202 Geneve
See on map
M1 4BT Manchester
See on map
1010 Wien
See on map
4001 Basel
See on map
1003 Lausanne
See on map
OX14 5EG Abingdon
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
1445 Strassen
See on map
2593 CE DEN HAAG
See on map
69280 Marcy l'Etoile
See on map
2340 Beerse
See on map
Participation ended
08860 Castelldefels
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Galway
See on map
92430 Marnes-La-Coquette
See on map
1262 Eysins
See on map
NW1 2BE London
See on map